Skip to content
Medical Health Aged Care, Science

Research grant to make gene therapy safer

Centenary Institute 2 mins read

A team led by Dr Chuck Bailey at the Centenary Institute has been awarded a National Health and Medical Research Council (NHMRC) Ideas Grant to develop safer and more effective gene therapies.

 

The project will focus on improving the safety and efficacy of adeno-associated virus (AAV)-based gene therapies, a promising treatment approach for many genetic disorders.

 

AAVs are naturally occurring viruses which can be harnessed to deliver good copies of genes into humans, thus enabling the treatment of diseases caused by faulty genes.

 

While AAV therapies have transformed treatment options for certain conditions, significant challenges remain. One major hurdle is the need for high doses to deliver genes effectively to hard-to-treat tissues, like muscle or the central nervous system.

 

These higher doses, required for diseases such as spinal muscular atrophy or Duchenne muscular dystrophy, can trigger unwanted immune responses, severe side effects and in some cases, life-threatening adverse events.

 

Dr Bailey’s team has discovered a new way to potentially improve AAV gene therapies by focusing on a specific protein named AAVR2. This protein plays a crucial role in helping the virus enter cells effectively. By boosting AAVR2 activity, the researchers aim to reduce the required dose of AAV, making the therapy safer, cheaper and more accessible to patients.

 

The team will apply this new method to target Pompe disease, a rare genetic condition affecting approximately 1 in 40,000 people. The condition causes severe muscle weakness, heart damage and breathing difficulties, significantly impacting mobility and quality of life.

 

“The support from the NHMRC enables us to address one of the biggest challenges in gene therapy today—improving safety and effectiveness,” said Dr Bailey.

 

“We’re excited to explore this innovative approach, which has the ability to transform treatment options for patients with rare and complex diseases.”

 

Grant Details

Grant Title: Enhanced adeno-associated virus vectors for safer gene therapies.

Chief Investigators: Dr Chuck Bailey, Dr Bijay Dhungel

Grant: $1,065,723

 

The NHMRC Ideas Grant program supports innovative and impactful research projects in all areas of health and medical research, from discovery to implementation.

 

[ENDS]

 


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients. 

For more information about the Centenary Institute, visit centenary.org.au

 


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: [email protected]

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.